Octreotide: A drug often used in the critical care setting but not well understood

Chest

Volumn 144, Issue 6, 2013, Pages 1937-1945

  Chan, Mallory M ^a   Chan, Michael M ^b   Mengshol, John Andrew ^a,c   Fish, Douglas N ^b   Chan, Edward D ^a,c,d  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d DEPARTMENT OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CYCLIC AMP; MIDODRINE; OCTREOTIDE; QUININE; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SULFONYLUREA; TERLIPRESSIN; VAPREOTIDE; VASOPRESSIN;

CHYLE; DRUG MECHANISM; DRUG STRUCTURE; ESOPHAGUS VARICES BLEEDING; HEPATORENAL SYNDROME; HUMAN; HYPOGLYCEMIA; INTENSIVE CARE; INTOXICATION; MOLECULAR BIOLOGY; PLEURA EFFUSION; PRIORITY JOURNAL; REVIEW; STOMACH VARICES BLEEDING;

AMINO ACID SEQUENCE; CRITICAL CARE; ESOPHAGEAL AND GASTRIC VARICES; HEPATORENAL SYNDROME; HUMANS; HYPOGLYCEMIA; OCTREOTIDE; PLEURAL EFFUSION; SOMATOSTATIN;

EID: 84890285273     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-0382     Document Type: Article

References (75)

1. Angel-Moreno Maroto A, Martínez-Quintana E, Suárez- Castellano L, Pérez-Arellano JL. Painful hypertrophic osteoarthropathy successfully treated with octreotide. The pathogenetic role of vascular endothelial growth factor (VEGF). Rheumatology (Oxford). 2005;44(10):1326-1327.
2. Gorshtein A, Gross DJ, Barak D, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and the associated lung neuroendocrine tumors: clinical experience with a rare entity. Cancer. 2012;118(3):612-619
3. Beglinger C, Drewe J. Somatostatin and octreotide: physiological background and pharmacological application. Digestion. 1999;60(suppl 2):2-8.
4. Low MJ. Neuroendocrinology. In: Kronenberg HM, Melmed S, Polonsky KS, et al, eds. Williams Textbook of Endocrinology. Philadelphia, PA: Saunders Elsevier; 2008:85-154.
5. Obery K. Carcinoid tumors, the carcinoid syndrome, and related disorders. In: Kronenberg HM, Melmed S, Polonsky KS, et al, eds. Williams Textbook of Endocrinology. Philadelphia, PA: Saunders Elsevier; 2008:1821-1840.
6. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20(3):157-198.
7. Lahlou H, Guillermet J, Hortala M, et al. Molecular signaling of somatostatin receptors. Ann N Y Acad Sci. 2004;1014:121-131.
8. Farrell SR, Raymond ID, Foote M, Brecha NC, Barnes S. Modulation of voltage-gated ion channels in rat retinal ganglion cells mediated by somatostatin receptor subtype 4. J Neurophysiol. 2010;104(3):1347-1354.
9. Reynaert H, van Rossen E, Uyama N, et al. Expression of somatostatin receptors in splanchnic blood vessels of normal and cirrhotic rats. Liver Int. 2007;27(6):825-831.
10. Tanaka T, Tani S. Inhibitory action of somatostatin on cAMP dependent pepsinogen secretion from rat gastric chief cells: involvement of pertussis toxin-sensitive G-protein. Biol Pharm Bull. 1994;17(3):415-418.
11. Werle M, Bernkop-Schnürch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30(4):351-367.
12. Bornschein J, Drozdov I, Malfertheiner P. Octreotide LAR: safety and tolerability issues. Expert Opin Drug Saf. 2009;8(6):755-768.
13. Sandostatin LAR Depot (octreotide acetate long-acting) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2012
14. Chandok N, Kamath PS, Blei A, et al. Randomised clinical trial: the safety and effi cacy of long-acting octreotide in patients with portal hypertension. Aliment Pharmacol Ther. 2012;35(8):904-912.
15. Lamberts SWJ, van der Lely A-J, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996;334(4):246-254.
16. Chadha MK, Lombardo J, Mashtare T, et al. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer Res. 2009;29(10):4127-4130.
17. Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism. 1996;45(8)(suppl 1):67-71.
18. Ludlam WH, Anthony L. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. Adv Ther. 2011;28(10):825-841.
19. Carmichael JD. Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits. Patient Prefer Adherence. 2012;6:73-82.
20. Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94(1):115-122.
21. van der Hoek J, de Herder WW, Feelders RA, et al. A singledose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab. 2004;89(2):638-645.
22. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46(3):922-938.
23. Imperiale TF, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology. 2001;33(4):802-807.
24. Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis [published correction appears in N Engl J Med. 2011;364(5):490. N Engl J Med. 2010;362(9):823-832.
25. Ben-Ari Z, Cardin F, McCormick AP, Wannamethee G, Burroughs AK. A predictive model for failure to control bleeding during acute variceal haemorrhage. J Hepatol. 1999;31(3):443-450.
26. García-Pagán JC, Reverter E, Abraldes JG, Bosch J. Acute variceal bleeding. Semin Respir Crit Care Med. 2012;33(1):46-54.
27. Benson AB, Austin GL, Berg M, et al. Transfusion-related acute lung injury in ICU patients admitted with gastrointestinal bleeding. Intensive Care Med. 2010;36(10):1710-1717.
28. Carbonell N, Pauwels A, Serfaty L, Fourdan O, Lévy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology. 2004;40(3):652-659.
29. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, Soares-Weiser K, Uribe M. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010;9(9):CD002907.
30. Silva G, Navasa M, Bosch J, et al. Hemodynamic effects of glucagon in portal hypertension. Hepatology. 1990;11(4):668-673.
31. Buonamico P, Sabbá C, Garcia-Tsao G, et al. Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: a double-blind randomized echo-Doppler study. Hepatology. 1995;21(1):134-139.
32. Bañares R, Albillos A, Rincón D, et al. Endoscopic treat ment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology. 2002;35(3):609-615.
33. Sung JJ, Chung SC, Yung MY, et al. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet. 1995;346(8991-8992):1666-1669.
34. Morales GF, Pereira Lima JC, Hornos AP, et al. Octreotide for esophageal variceal bleeding treated with endoscopic sclerotherapy: a randomized, placebo-controlled trial. Hepatogastroenterology. 2007;54(73):195-200.
35. Villanueva C, Piqueras M, Aracil C, et al. A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding. J Hepatol. 2006;45(4):560-567.
36. Gøtzsche PC, Hróbjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. Cochrane Database Syst Rev. 2008;3(3):CD000193.
37. D'Amico G, Pagliaro L, Pietrosi G, Tarantino I. Emergency sclerotherapy versus vasoactive drugs for bleeding oesophageal varices in cirrhotic patients. Cochrane Database Syst Rev. 2010;17(3):CD002233.
38. Wells M, Chande N, Adams P, et al. Meta-analysis: vasoactive medications for the management of acute variceal bleeds. Aliment Pharmacol Ther. 2012;35(11):1267-1278.
39. Calès P, Masliah C, Bernard B, et al; French Club for the Study of Portal Hypertension. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N Engl J Med. 2001;344(1):23-28.
40. McLaughlin SA, Crandall CS, McKinney PE. Octreotide: an antidote for sulfonylurea-induced hypoglycemia. Ann Emerg Med. 2000;36(2):133-138.
41. Smith SW. Drugs and pharmaceuticals: management of intoxication and antidotes. In: Luch A, ed. Mol Clin Environ Toxicol. Switzerland: Birkhauser Verlag; 2010:397-460.
42. Glatstein M, Scolnik D, Bentur Y. Octreotide for the treatment of sulfonylurea poisoning. Clin Toxicol. 2012;50(9):795-804.
43. Mincher L, Evans J, Jenner MW, Varney VA. The successful treatment of chylous effusions in malignant disease with octreotide. Clin Oncol (R Coll Radiol). 2005;17(2):118-121.
44. Hung WP, Wang JN, Chang HK, Wu JM. Octreotide therapy in two children with intractable postoperative chylothorax. Int J Cardiol. 2011;146(3):e63-e65.
45. Shah D, Sinn JK. Octreotide as therapeutic option for congenital idiopathic chylothorax: a case series. Acta Paediatr. 2012;101(4):e151-e155.
46. Abid S, Jafri W, Hamid S, et al. Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial. Am J Gastroenterol. 2009;104(3):617-623.
47. Corley DA, Cello JP, Adkisson W, Ko WF, Kerlikowske K. Octreotide for acute esophageal variceal bleeding: a metaanalysis. Gastroenterology.2001;120(4) :946-954.
48. Calès P. Vapreotide acetate for the treatment of esophageal variceal bleeding. Expert Rev Gastroenterol Hepatol. 2008;2(2):185-192.
49. Platt R, Calès P. Meta-analysis of early combination of vapreotide to endoscopic treatment in variceal bleeding. Gastroenterology. 2007;132(4 suppl 1):A799-A800.
50. Ginès A, Escorsell A, Ginès P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105(1):229-236.
51. Arroyo V, Ginès P, Gerbes AL, et al. Defi nition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23(1):164-176.
52. Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet. 2003;362(9398):1819-1827.
53. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol. 2003;38(suppl 1):S69-S89.
54. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42(2):439-447.
55. Kiser TH, Maclaren R, Fish DN. Treatment of hepatorenal syndrome. Pharmacotherapy. 2009;29(10):1196-1211.
56. Møller S, Brinch K, Henriksen JH, Becker U. Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis. J Hepatol. 1997;26(5):1026-1033.
57. Kaffy F, Borderie C, Chagneau C, et al. Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients [Letter]. J Hepatol. 1999;30(1):174.
58. Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant. 2005;20(9):1813-1820.
59. Kalambokis G, Economou M, Fotopoulos A, et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol. 2005;100(4):879-885.
60. Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology. 2003;38(1):238-243.
61. Angeli P, Volpin R, Piovan D, et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology. 1998;28(4):937-943.
62. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29(6):1690-1697.
63. Esrailian E, Pantangco ER, Kyulo NL, Hu K-Q, Runyon BA. Octreotide/Midodrine therapy signifi cantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci. 2007;52(3):742-748.
64. Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol. 2009;43(7):680-685.
65. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40(1):55-64.
66. Rowden AK, Fasano CJ. Emergency management of oral hypoglycemic drug toxicity. Emerg Med Clin North Am. 2007;25(2):347-356., abstract viii.
67. Dougherty PP, Klein-Schwartz W. Octreotide's role in the management of sulfonylurea-induced hypoglycemia. J Med Toxicol. 2010;6(2):199-206.
68. Fasano CJ, O'Malley G, Dominici P, Aguilera E, Latta DR. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. Ann Emerg Med. 2008;51(4):400-406.
69. Phillips RE, Looareesuwan S, Molyneux ME, Hatz C, Warrell DA. Hypoglycaemia and counterregulatory hormone responses in severe falciparum malaria: treatment with Sandostatin. Q J Med. 1993;86(4):233-240.
70. Doerr CH, Allen MS, Nichols FC III, Ryu JH. Etiology of chy lothorax in 203 patients. Mayo Clin Proc. 2005;80(7):867-870.
71. Huggins JT. Chylothorax and cholesterol pleural effusion. Semin Respir Crit Care Med. 2010;31(6):743-750.
72. Kalomenidis I. Octreotide and chylothorax. Curr Opin Pulm Med. 2006;12(4):264-267.
73. Jiang H, Deng XF, Duan CM, et al. Somatostatin receptors SSTR2 and SSTR5 are expressed in the human thoracic duct. Lymphology. 2011;44(1):21-28.
74. Chan EH, Russell JL, Williams WG, Van Arsdell GS, Coles JG, McCrindle BW. Postoperative chylothorax after cardiothoracic surgery in children. Ann Thorac Surg. 2005;80(5):1864-1870.
75. Yildirim AE, Altun R, Can S, et al. Idiopathic chylous ascites treated with total parenteral nutrition and octreotide. A case report and review of the literature. Eur J Gastroenterol Hepatol. 2011;23(10): 961-963.